S549
Clinical – Head & neck
ESTRO 2026
Jonker 5 , Anton Rink 1 , Erik D. van Werkhoven 1 , Margarethus M. Paulides 6,1 , Remi A. Nout 1 , Sergio Curto 1 , Michiel Kroesen 1 1 Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 2 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 3 Department of Geriatrics, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 4 Department of Otorhinolaryngology - Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 5 Department of Oral and Maxillofacial Surgery, Erasmus MC Cancer Institute, Rotterdam, Netherlands. 6 Electrical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands Purpose/Objective: Treatment of locally advanced head and neck cancer (LAHNC) with (chemo)radiation faces a major challenge, as around 30 % of patients experience locoregional recurrences, mainly within the high-dose region. 1,2 This highlights the need to improve therapy. Hyperthermia (HT) enhances radiotherapy (RT) effectiveness and has shown clinical benefit in multiple cancers.3,4 In head and neck cancer, clinical evidence for HT is limited, but a meta-analysis suggests a benefit for tumor response.5 However, current commercial devices cannot adequately focus heat to deep-seated tumors, highlighting the lack of dedicated head and neck hyperthermia applicators. To address this challenge, we developed the HyperCollar3D (HC3D), an innovative device capable of delivering focused hyperthermia to both deep-seated primary tumors and pathological neck nodes (Fig. 1). We initiated a phase I trial to investigate the feasibility and safety of HT administered with the HC3D, concurrent with curative (chemo)radiation for LAHNC, and present the first in-human real-world data.
oropharynx. Overall, 72% of patients received concomitant chemotherapy. The mean baseline weight was 71.14 kg, with an average BMI of 25.29 kg/m ² . Mean weight loss during treatment was 1.75 kg (SD 2.13). Oral nutritional supplementation was required in 60% of patients.The relative reduction of the muscle compartment was 21.59%, compared to 48.74% in the adipose compartment (2). A statistically significant correlation was observed between the evolution of both compartments (p < 0.0001). Regression analysis did not show an overall statistically significant association (p = 0.125) between sex, age, tumor location, chemotherapy treatment and muscle loss relative to loss of fat mass. Individually, none of the variables reached statistical significance, but age showed a trend toward significance (p = 0.050). Patients over 65 years experienced greater fat mass loss throughout treatment.
Conclusion: During radical radiotherapy or concomitant chemoradiotherapy for head and neck tumors, the cervical adipose compartment underwent a more pronounced decrease than cervical musculature. Among the clinical variables analyzed, age was the only factor approaching statistical significance in relation to fat mass loss dynamics. These results suggest that monitoring adipose tissue and muscle changes may help identify patients at higher risk of anatomical variation who could benefit from early replanning. Keywords: Muscle and adipose compartment alterations Digital Poster Highlight 795 First in-human experience in the TANCA-I trial (NCT06761937), adding thermotherapy to radiotherapy in locally advanced head and neck cancer patients. Tessa L. Coenraad 1 , Jos B.W. Elbers 1 , Patrick V. Granton 1 , Martine Franckena 1 , Lisa Tans 1 , Gerda M. Verduijn 1 , Esther van Meerten 2 , Harmke A. Polinder- Bos 3 , Jose A.U. Hardillo 4 , Aniel Sewnaik 4 , Brend P.
Made with FlippingBook - Share PDF online